|

Binimetinib Clinical Trials

14 actively recruiting trials across 7 locations

Also known as: ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, Binimetinib Oral, MEK 162, MEK-162, MEK162, MEKTOVI, Mektovi, Mektovi, PF-06811462, MEK162

Other4 trials

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Melanoma Metastasized to the Brain and Steroids
Phase 2
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Phase 1

Birmingham, Alabama3 trials

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

University of Alabama at Birmingham Cancer Center

Phase 2
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

O'Neal Comprehensive Cancer Center

Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Bethesda, Maryland2 trials

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

National Institutes of Health Clinical Center

Phase 2
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

National Institutes of Health Clinical Center

Phase 2

Fayetteville, Arkansas1 trial

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Highlands Oncology Group

Phase 1

La Jolla, California1 trial

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

UC San Diego Moores Cancer Center

Phase 2

Los Angeles, California1 trial

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

UCLA Medical Center

Phase 1/2

Iowa City, Iowa1 trial

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

University of Iowa

Phase 1

Houston, Texas1 trial

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.